

Query too big to Preview

chain nodes :

7 8 9 10 11 12 13 29 30 31 32 33 34 35 36 50

ring nodes :

1 2 3 4 5 6 18 19 20 21 22 23 24 25 26 40 41 42 43 44  
45 46 47 48 49

chain bonds :

1-33 1-34 2-7 3-31 3-32 4-29 4-30 5-20 6-35 6-36 7-8 7-9 7-10  
10-11 11-13 11-12 11-50

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 18-19 18-22 19-20 20-21 21-22 21-23  
22-26 23-24 24-25 25-26 40-41 40-45 41-42 42-43 43-44 44-45  
44-46 45-49 46-47 47-48 48-49

exact/norm bonds :

1-2 1-6 1-33 1-34 2-3 2-7 3-4 3-31 3-32 4-5 4-29 4-30 5-6  
5-20 6-35 6-36 7-8 7-9 7-10 10-11 11-13 11-12 11-50 18-19  
18-22 19-20 20-21 44-46 45-49 46-47 47-48 48-49

normalized bonds :

21-22 21-23 22-26 23-24 24-25 25-26 40-41 40-45 41-42 42-43  
43-44 44-45

isolated ring systems :

containing 18 :

G1:O,S,N

G2:H,CH3

G3:C,O

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS  
10:CLASS 11:CLASS 12:CLASS 13:CLASS 18:Atom 19:Atom 20:Atom  
21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 29:CLASS 30:CLASS  
31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 40:Atom  
41:CLASS 42:Atom 43:Atom 44:Atom 45:Atom 46:Atom 47:Atom 48:Atom  
49:Atom 50:CLASS

10/672949

isolated ring systems :  
containing 18 :

G1:O,S,N

G2:H,CH3

G3:C,O

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS 12:CLASS 13:CLASS 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom  
24:Atom 25:Atom 26:Atom 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS  
34:CLASS 35:CLASS 36:CLASS 40:Atom 41:CLASS 42:Atom 43:Atom 44:Atom 45:Atom  
46:Atom 47:Atom 48:Atom 49:Atom 50:CLASS

L5 STRUCTURE UPLOADED

=> s 15

SAMPLE SEARCH INITIATED 18:45:13 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 41 TO ITERATE

100.0% PROCESSED 41 ITERATIONS 12 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 436 TO 1204  
PROJECTED ANSWERS: 32 TO 446

L6 12 SEA SSS SAM L5

=> d 16 1 5 10

L6 ANSWER 1 OF 12 REGISTRY COPYRIGHT 2005 ACS on STN

RN 860023-06-9 REGISTRY

ED Entered STN: 12 Aug 2005

CN Quinoline, 1-acetyl-1,2,3,4-tetrahydro-6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-3,3-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

OTHER NAMES:


CN 1-[6-[2-[4-(1H-Indazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-3,4-dihydro-2H-quinolin-1-yl]ethanone dihydrochloride

MF C26 H33 N5 O . 2 Cl H

SR CA

LC STN Files: CA, CAPLUS


CRN (860116-21-8)



● 2 HCl

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 5 OF 12 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 676117-88-7 REGISTRY  
ED Entered STN: 18 Apr 2004  
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-1-pentyl- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-1-pentyl-3,4-dihydro-1H-quinolin-2-one  
FS 3D CONCORD  
MF C30 H40 N4 O S  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 10 OF 12 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 676115-73-4 REGISTRY  
ED Entered STN: 18 Apr 2004  
CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one  
FS 3D CONCORD  
MF C24 H28 N4 O2

10/672949

SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 15 sss full  
FULL SEARCH INITIATED 18:45:57 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 880 TO ITERATE

100.0% PROCESSED 880 ITERATIONS 315 ANSWERS  
SEARCH TIME: 00.00.01

L7 315 SEA SSS FUL L5

=> save 17  
ENTER NAME OR (END):ten672949/a  
ANSWER SET L7 HAS BEEN SAVED AS 'TEN672949/A'

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	167.71	342.16
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.46

FILE 'CAPLUS' ENTERED AT 18:46:21 ON 30 SEP 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Sep 2005 VOL 143 ISS 15

10/672949

FILE LAST UPDATED: 29 Sep 2005 (20050929/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 17

L8 12 L7

=> d 18 1-12 bib abs fhitstr

L8 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:638875 CAPLUS

DN 143:153404

TI Preparation of N-substituted piperidine and piperazine derivatives  
dopamine D2 and serotonin 2A receptor antagonists

IN Cho, Stephen Sung Yong; Gregory, Tracy Fay; Guzzo, Peter Robert; Howard,  
Harry Ralph, Jr.; Nikam, Sham Shridhar; Surman, Matthew David; Walters,  
Michael Anthony

PA Warner-Lambert Company Llc., USA

SO PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005066165	A1	20050721	WO 2004-IB4239	20041220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2003-533761P P 20031231


GI



AB This invention relates to N-substituted piperidine and piperazine derivs. (shown as I; variables defined below; e.g. [5-[2-[4-(benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-2,3-dihydroindol-1-yl] (4-fluorophenyl)methanone (shown as II)), pharmaceutical compns. contg. them and their use in the treatment of central nervous system and other disorders. Although the methods of prepn. are not claimed, example preps. and/or characterization data for .apprx.160 I are included. For example, II was prepd. in 98 % yield by coupling 3-[4-[2-(3,3-dimethyl-2,3-dihydro-1H-indol-5-yl)ethyl]piperazin-1-yl]benzo[d]isothiazole with 4-fluorobenzoyl chloride; the benzo[d]isothiazole reactant was prepd. in 79 % yield by redn. of 5-[2-[4-(benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-1,3-dihydroindol-2-one, which was prepd. in 96 % yield from 3-(piperazin-1-yl)benzo[d]isothiazole and 5-(2-chloroethyl)-3,3-dimethyl-1,3-dihydroindol-2-one, which was prepd. in 45 % yield by redn. of 5-(2-chloroethyl)-3,3-dimethyl-1,3-dihydroindol-2-one, which was prepd. in >96 % yield from chloroacetyl chloride and 3,3-dimethyl-1,3-dihydroindol-2-one. For I: M = E-R9, L-T-R9, T-D-R9; U is S, O, SO, SO2, CH2 or NR3; V is N or C; Z is N or C; A is -(CH2)mO-, -(CH2)mNR4-, or -(CH2)mC(R5R6)-, wherein R5 and R6 = H, (C1-C4) alkyl (un)substituted with 1-3 F atoms, (C1-C4) alkoxy (un)substituted with 1-3 F atoms, hydroxy, and aminoalkyl; or R5 and R6 together form a carbonyl, and wherein m = 1-4. R1 and R2 = H, (C1-C4) alkyl (un)substituted with 1-3 F atoms, (C1-4) alkoxy (un)substituted with 1-3 F atoms, halogen, nitro, cyano, amino, (C1-C4) alkylamino and di(C1-C4) alkylamino; R3 and R4 = H, (C1-C4) alkyl (un)substituted with 1-3 F atoms and (C1-C4) alkoxy (un)substituted with 1-3 F atoms; or, when U is NR3, one of R1 and R2 can form, together with the C to which it is attached, and together with R3 and the N to which it is attached, a heterocyclic ring contg. 4-7 ring members of which 1-3 ring members can be N, O and S, and of which the remaining ring members are C, with the proviso that when R3 forms a ring with one of R1 and R2, the other of R1 and R2 is absent. X is -[C(R11)(R12)]o-, wherein R11 and R12 = H and (C1-C4) alkyl (un)substituted with 1-3 F atoms, and wherein o = 0-3, with the proviso that when W is absent, o .gtoreq.2; W is -[C(R13)(R14)]p-, wherein R13 and R14 = H and (C1-C4) alkyl (un)substituted with 1-3 F atoms, and wherein p = 0-4, with the proviso that when X is absent, p .gtoreq.2; R7 and R8 = halo, R1 and -OR1; or R7,

when attached to a C adjacent to one of the C atoms shared by both the Ph ring to which R7 is attached and the ring contg. W, N and X, forms, together with a C atom of X or a C atom of W, a satd. carbocyclic ring contg. 3-6 C atoms. R9 = Ph, phenoxy, benzyloxy, and phenylamino, wherein the Ph moieties are (un)substituted with 1-3 halo, (C1-C3) alkyl (un)substituted with 1-3 F atoms, (C1-C3) alkoxy (un)substituted with 1-3 F atoms, nitro, cyano, amino, and (C1-C3) alkylamino; or R9 is a pyrrolidine, piperidine or morpholine ring wherein the point of attachment to D, T or E is the ring N, and wherein said pyrrolidine, piperidine or morpholine ring can be (un)substituted with 1 or 2 Me, amino, (C1-04) alkylamino, and di(C1-C4) alkylamino; or R9 is a furan, thiophene, or pyrazole ring (un)substituted with 1-2 (C1-C4) alkyl groups; or R9 is (C1-C6) straight or branched alkyl or (C3-C6) cycloalkyl, wherein said straight, branched and cyclic alkyl moieties are be (un)substituted with 1-3 halo atoms or (C1-C4) alkoxy (un)substituted with 1-3 F atoms; or R9 is halogen, nitro, cyano, amino, (C1-C4) alkylamino, di(C1-C4) alkylamino or OR1, wherein the alkyl moieties of (C1-C4) alkylamino and di(C1-C4) alkylamino are (un)substituted with an amino, (C1-C4) alkylamino, or di(C1-C4) alkylamino group; E is -C(O)-, -S(O)- or -SO2-; T is -C(O)- or -CO2-; L is -(CH2)n wherein n = 0-3; D is -(CHR10)q-, wherein q = 1-3, or NR10; R10 is H or straight or branched (C1-C3) alkyl.

IT **860023-07-0P**, 1-[6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-7-chloro-4,4-dimethyl-3,4-dihydro-2H-quinolin-1-yl]ethanone  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; prepn. of N-substituted piperidine and piperazine derivs. dopamine D2 and serotonin 2A receptor antagonists)  
 RN 860023-07-0 CAPLUS  
 CN Quinoline, 1-acetyl-6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-7-chloro-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:756696 CAPLUS  
 DN 141:260561  
 TI A preparation of focused library of quinolinecarboxylic acid derivatives, useful as caspase enzyme inhibitors  
 IN Ivashchenko, Alexander Vasilievich; Kobak, Vladimir Vasilievich; Kysil, Volodymyr Mikhailovich; Kuzovkova, Yulia Aleksandrovna; Ilyin, Alexey Petrovich; Kravchenko, Dmitri Vladimirovich; Tkachenko, Sergey Yevgenievich; Khvat, Alexander Viktorovich; Okun, Ilya Matusovich  
 PA Chemical Diversity Research Institute, Ltd., Russia  
 SO PCT Int. Appl., 182 pp.  
 CODEN: PIXXD2



DT Patent  
LA Russian  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004078731	A1	20040916	WO 2004-RU81	20040303
	W:	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	RU 2229475	C1	20040527	RU 2003-106182	20030306
	RU 2260002	C2	20050910	RU 2003-124470	20030808
	RU 2257385	C2	20050727	RU 2003-125937	20030826
PRAI	RU 2003-106182	A	20030306		
	RU 2003-124470	A	20030808		
	RU 2003-125937	A	20030826		
OS	MARPAT 141:260561				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to a prepn. of focused library of quinolinecarboxylic acid derivs. of formulas I, II, and III [wherein: R1 is H, halogen, CF3, CN, NO2, or OH, etc.; R2 is halogen, (un)substituted alkyl, NH2, or OH; R3 is H, halogen, alk(en)yl, (un)substituted NH2 or OH; R4 is H, CO2H, or C(O)NH2; R5 is (un)substituted hydroxy- or mercapto-group, NH2, or heterocycle, etc.; R6 is H or other inert substituent; R7 is H, CN, CF3, NO2, NH2, alkylsulfonyl, or hydroxysulfonyl, etc.; W is O, NH, or N-alkyl, etc.], useful as caspase enzyme inhibitors (no biol. data). For instance, quinolinecarboxylate deriv. IV was prepd. via esterification of quinolinecarboxylic acid deriv. V by 2-FC6H4CH2Br with a yield of 74% (example 5).


IT 591242-64-7P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(prepn. of focused library of quinolinecarboxylic acid derivs. useful as caspase enzyme inhibitors)

RN 591242-64-7 CAPLUS



CN 4-Quinolinecarboxylic acid, 2-methyl-, 2-[4-(1,1-dioxido-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:412926 CAPLUS  
DN 140:423706  
TI Preparation of phenylalkyl and pyridylalkyl piperazine derivatives as  
antagonists of dopamine D2 receptors and of serotonin 2A (5HT2A) receptors  
IN Cho, Stephen Sung Yong; Davis, Jamie Marie; Graham, James Michael;  
Gregory, Tracy Fay; Howard, Harry Ralph, Jr.; Nikam, Sham Shridhar;  
Walters, Michael Anthony  
PA Warner-Lambert Company LLC, USA  
SO PCT Int. Appl., 185 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2004041793	A1	20040521	WO 2003-IB4805	20031027	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	CA 2505397	AA	20040521	CA 2003-2505397	20031027	
	EP 1562919	A1	20050817	EP 2003-753871	20031027	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
	US 2004186108	A1	20040923	US 2003-703333	20031107	
PRAI	US 2002-425219P	P	20021108			
	WO 2003-IB4805	W	20031027			
OS	MARPAT 140:423706					
GI						



AB The title compds. [I; M = N(R<sub>2</sub>)WR<sub>3</sub>, II; R<sub>1</sub> = (un)substituted 1,2-benzisothiazoyl, 1,2-benzisoxazoyl, pyridyl, etc.; A = (CH<sub>2</sub>)<sub>n</sub>(CH<sub>2</sub>); n = 0-3; U = C, N; m = 1-2; X<sub>1</sub>-X<sub>3</sub> = H, halo, alkyl, etc.; R<sub>2</sub> = H, alkyl, arylalkyl, etc.; W = CO, CO<sub>2</sub>, CONH, SO<sub>2</sub>, SO<sub>2</sub>NR<sub>4</sub>; R<sub>3</sub>, R<sub>4</sub> = alkyl, arylalkyl, alkenyl, etc.], useful in the treatment of central nervous system and other disorders, were prepd. Thus, amidation of 4-[2-(4-1,2-benzisothiazol-3-ylpiperazin-1-yl)ethyl]phenylamine with trimethylacetyl chloride in the presence of Et<sub>3</sub>N in THF afforded the amide III. The exemplified compds. I showed IC<sub>50</sub> values of .1 to req. 1 .mu.M in dopamine D<sub>2</sub> receptor binding assay and in serotonin 2A binding assay. The pharmaceutical compn. comprising the compd. I is claimed.


IT 690976-58-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenylalkyl and pyridylalkyl piperazines as antagonists of dopamine D<sub>2</sub> receptors and of serotonin 2A (5HT<sub>2A</sub>) receptors)

RN 690976-58-0 CAPLUS

CN 8-Quinolinesulfonamide, N-[4-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:287843 CAPLUS

DN 140:321381

TI Preparation of heterocyclic substituted piperazines for the treatment of schizophrenia

IN Davis, Jamie Marie; Gregory, Tracy Fay; Walters, Michael Anthony

PA Warner-Lambert Company LLC, USA

SO PCT Int. Appl., 90 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004029048	A1	20040408	WO 2003-IB4113	20030918
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2500115	AA	20040408	CA 2003-2500115	20030918
	EP 1546145	A1	20050629	EP 2003-798314	20030918
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003014796	A	20050726	BR 2003-14796	20030918
	US 2004067960	A1	20040408	US 2003-672949	20030926
PRAI	US 2002-413839P	P	20020926		
	WO 2003-IB4113	W	20030918		
OS	MARPAT 140:321381				
GI					



AB The title compds. [I; Ar = 1,2-benzisothiazoyl, 1,2-benzisothiazoyl-1-oxide, naphthyl, pyridyl, etc.; with the proviso that Ar can not be attached to the piperazine ring via a Ph ring of Ar; Y = N, CH; A = (CH<sub>2</sub>)<sub>n</sub>CH<sub>2</sub> (wherein n = 1-4, one of the CH<sub>2</sub> groups that is not adjacent to the piperazine nitrogen can be replaced by an oxygen atom); R<sub>2</sub>, R<sub>3</sub> = H, alkyl, fluoroalkyl, alkoxy, etc.; Q = (un)satd. (un)substituted 5-7 membered monocyclic heterocyclic ring contg. 1-3 heteroatoms selected from O, N and S], useful in the treatment of central nervous system disorders, were prep'd. Thus, reacting 3-methylbut-2-enoic acid (2-{2-[4-(1,2-

benzisothiazol-3-yl)-piperazin-1-yl]ethyl}phenyl)amide (prepn. given) with  $\text{AlCl}_3$  in  $\text{C}_6\text{H}_5\text{Cl}$  afforded 8-[2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one which showed  $\text{K}_i$  of .1 to req. 1  $\mu\text{M}$  against dopamine D2 receptor binding, and  $\text{K}_i$  of .1 to req. 1  $\mu\text{M}$  against 5-HT2A receptor binding. The pharmaceutical compn. comprising the compd. I is claimed.


IT **677708-42-8P**

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclic substituted piperazines for the treatment of schizophrenia)

RN 677708-42-8 CAPLUS

CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-benzoyl-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:267327 CAPLUS

DN 140:287412

TI Preparation of piperazines as dopamine D2 and serotonin 5HT2A receptors inhibitors for the treatment of central nervous system disorders, in particular schizophrenia

IN Andreana, Tonja Lynn; Cho, Stephen Sung Yong; Graham, James Michael; Gregory, Tracy Fay; Howard, Harry Ralph, Jr.; Kornberg, Brian Edward; Nikam, Sham Shridhar; Pflum, Derek Andrew

PA Warner-Lambert Company LLC, USA

SO PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026864	A1	20040401	WO 2003-IB3902	20030905
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				


PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,  
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2499326 AA 20040401 CA 2003-2499326 20030905  
 EP 1546143 A1 20050629 EP 2003-797433 20030905  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR 2003014393 A 20050719 BR 2003-14393 20030905  
 US 2004138230 A1 20040715 US 2003-660908 20030912  
 PRAI US 2002-411475P P 20020917  
 US 2002-416355P P 20021004  
 WO 2003-IB3902 W 20030905  
 OS MARPAT 140:287412  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [wherein X =S, O, SO, SO<sub>2</sub>, CH<sub>2</sub>, NH and derivs.; Y, Z = independently N or CH; A = (CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>, (CH<sub>2</sub>)<sub>m</sub>O, (CH<sub>2</sub>)<sub>m</sub>NR<sub>9</sub>, (CH<sub>2</sub>)<sub>m</sub>C(R<sub>7</sub>R<sub>8</sub>); R<sub>7</sub>, R<sub>8</sub> = independently (un)substituted alkyl, alkoxy, or CR<sub>7</sub>R<sub>8</sub> = carbonyl; m = 1-4; R<sub>4</sub>, R<sub>5</sub> = independently H, (un)substituted alkyl, alkoxy, or when X = NR<sub>6</sub> and derivs., CR<sub>4</sub>R<sub>5</sub>R<sub>6</sub>N = 4-7 membered heterocyclyl ring, with the proviso that when R<sub>9</sub>R<sub>4</sub> or R<sub>9</sub>R<sub>5</sub> = a ring, the other of R<sub>4</sub> and R<sub>5</sub> is absent; R<sub>9</sub> = H, (un)substituted alkyl, alkoxy; R<sub>6</sub> = H, (un)substituted alkyl, alkoxy; R<sub>1</sub> = H, (un)substituted alkyl; R<sub>2</sub>, R<sub>3</sub> = independently H, halo, hetero/aryl, (un)substituted aryl/heteroarylalkyl, alkoxy, etc.; V, W = independently CH<sub>2</sub> and derivs. or CH and derivs.; and their pharmaceutically acceptable salts] were prepd. s dopamine D<sub>2</sub> and serotonin 5HT<sub>2A</sub> receptors inhibitors for treating central nervous system disorders, in particular schizophrenia (no data). For example, II.bul.MeSO<sub>3</sub>H was prepd. by acylation of 3-chloro-2-methylaniline with 3,3-diethylacryloyl chloride, one-pot Friedel-Craft alkylation with chloroacetyl chloride and cyclization in the presence of AlCl<sub>3</sub> to chloroacetylquinoline intermediate, redn. to chloroethylquinoline III, alkylation of 3-(piperazin-1-yl)benzo[d]isothiazole hydrochloride with III, followed by salt formation of II with methanesulfonic acid. II acted as dopamine D<sub>2</sub> and serotonin 5HT<sub>2A</sub> receptors inhibitors with a K<sub>i</sub> value of 0.9 nM and 1 nM, resp. Thus, I and their formulations are useful for treating central nervous system disorders, in particular schizophrenia and depression.


IT **676117-35-4P**, 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetamide  
 RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)  
 (drug candidate; prepn. of piperazines for treating of central nervous system disorders, in particular schizophrenia)

RN 676117-35-4 CAPLUS  
 CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl-2-oxo- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2002:732486 CAPLUS  
DN 138:331185  
TI New 3-benzisothiazolyl and 3-benzisoxazolylpiperazine derivatives with  
atypical antipsychotic binding profile  
AU Orjales, Aurelio; Mosquera, Ramon; Toledo, Antonio; Pumar, Carmen;  
Labeaga, Luis; Innerarity, Ana  
CS Research Department, FAES FARMA, S.A., Leioa, E-48940, Spain  
SO European Journal of Medicinal Chemistry (2002), 37(9), 721-730  
CODEN: EJMCA5; ISSN: 0223-5234  
PB Editions Scientifiques et Medicales Elsevier  
DT Journal  
LA English  
OS CASREACT 138:331185  
AB New 3-benzisothiazolyl and 3-benzisoxazolylpiperazine derivs. were  
synthesized and their 5-HT1A, 5-HT2A and D2 receptor binding affinities  
evaluated. The compds. displayed high affinity for the 5-HT2A receptor  
combined with moderate to low 5-HT1A and D2 affinities. Two of them have  
been selected for further pharmacol. studies to be evaluated as potential  
atypical antipsychotics.  
IT **516509-59-4P**  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(benzisothiazolyl and benzisoxazolylpiperazine derivs. with atypical  
antipsychotic binding profile)  
RN 516509-59-4 CAPLUS  
CN 2(1H)-Quinolinone, 1-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-  
3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1999:10184 CAPLUS  
DN 130:38398  
TI Quinolin-2(1H)-one derivatives as serotonin antagonists  
IN McCort, Gary; Hoornaert, Christian; Duclos, Olivier; Cadilhac, Caroline;  
Guilpain, Eric  
PA Synthelabo S. A., Fr.  
SO Fr. Demande, 38 pp.  
CODEN: FRXXBL  
DT Patent  
LA French  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	FR 2761067	A1	19980925	FR 1997-3388	19970320
	FR 2761067	B1	19990423		
PRAI	FR 1997-3388		19970320		
OS	MARPAT 130:38398				
GI					





I



II

AB Quinolinones I [R1, R2 = H, halogen, NH2, OH, NO2, CN, alkyl, alkoxy, CF3, OCF3, CO2R5, carbamoyl, SR5, SO2R5, NHNCOR5, NHSO2R5, NR52 (R5 = alkyl); R3 = H, (un)substituted alkyl; R4 = H, halogen, OH, NO2, CN, alkyl, alkoxy, CF3, CONH2, NHSO2Me; m = 2-4; Z = N, CH; A = O, NH, S, NR5] were prepd. for use as serotonin antagonists (no data). Thus, the quinolinone II was obtained from the chloroethylquinolinone and the piperidinylisoxazole fragments.


IT **216674-97-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of quinolinone derivs. as serotonin antagonists)

RN 216674-97-4 CAPLUS

CN 2(1H)-Quinolinone, 7-fluoro-4-[2-[4-(6-fluoro-1H-indazol-3-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




L8 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:656492 CAPLUS

DN 126:8030

TI Synthesis and Evaluation of Heterocyclic Carboxamides as Potential

- Antipsychotic Agents
- AU Norman, Mark H.; Navas, Frank, III; Thompson, James B.; Rigdon, Greg C.  
 CS Division of Chemistry, Glaxo Wellcome Inc., Research Triangle Park, NC, 27709, USA  
 SO Journal of Medicinal Chemistry (1996), 39(24), 4692-4703  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 AB Heterocyclic analogs of 1192U90, 2-amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)benzamide hydrochloride (1), were prepd. and evaluated as potential antipsychotic agents. These analogs were evaluated in vitro for their binding to the dopamine D2, serotonin 5-HT2, and serotonin 5-HT1a receptors and in vivo for their ability to antagonize the apomorphine-induced climbing response in mice. Nine different types of heterocyclic carboxamides were studied in this investigation (i.e., pyridine-, thiophene-, benzothiophene-, quinoline-, 1,2,3,4-tetrahydroquinoline-, 2,3-dihydroindole-, indole-, benzimidazole-, and indazolecarboxamides). Two derivs. exhibited potent in vivo activities comparable to 1: 3-amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-2-pyridinecarboxamide (16) and 3-amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-2-thiophenecarboxamide (29). Furthermore, these derivs. were found to be much less active in behavioral models predictive of extrapyramidal side effects than in the mouse climbing assay, which predicts antipsychotic activity. Carboxamides 16 and 29 were selected for further evaluation as potential backup compds. to 1.
- IT **161940-16-5P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. of benzisothiazolylpiperazinylbutyl heterocyclic carboxamide antipsychotics)
- RN 161940-16-5 CAPLUS  
 CN 8-Quinolinecarboxamide, N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)




- L8 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1995:682542 CAPLUS  
 DN 123:83356  
 TI Preparation of 3-(1-piperazinyl)-1,2-benzisothiazole derivatives with antipsychotic effect  
 IN Fukuda, Yoshimasa; Sasaki, Toshiro; Nakatani, Yuuko; Ichimaru, Yasuyuki; Imanishi, Taiichiro  
 PA Meiji Seika K. K., Japan  
 SO PCT Int. Appl., 95 pp.  
 CODEN: PIXXD2  
 DT Patent


LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9418197	A1	19940818	WO 1994-JP159	19940203
	W: CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 635506	A1	19950125	EP 1994-905841	19940203
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	CN 1103534	A	19950607	CN 1994-190042	19940203
	CN 1050604	B	20000322		
	US 5599815	A	19970204	US 1994-318857	19941220
PRAI	JP 1993-17505	A	19930204		
	WO 1994-JP1	A	19940104		
	WO 1994-JP159	W	19940203		
OS	MARPAT 123:83356				
GI					



I



AB Compds. represented by general formula [I;  $n = 2-4$ ;  $W =$  heterocyclyl, e.g.,  $Q - Q_2$ ;  $m = 0-2$ ;  $A = CH_2, CH, N, NH$ ;  $B = CH_2, CH, N, NH, S$ ; provided that both  $A$  and  $B$  .noteq.  $N$  or  $NH$ ;  $X = CH, N, S$ , bond;  $Y = CH, N$ ;  $R_1 = H$ , halo, lower (halo)alkyl, (un)substituted Ph, OH,  $NO_2$ , lower alkoxy,  $NH_2$ , cyano;  $R_2, R_3 = H$ , halo, lower (halo)alkyl or alkoxy,  $NH_2$ , cyano, provided that when  $X =$  bond,  $R_2$  is not present; or  $R_2R_3 = (CH_2)_p$  (wherein  $p = 3-5$ )] and pharmacol. acceptable salts thereof, reduced in the adverse effect against the extrapyramidal system and hence useful as an antipsychotic agent with few side effects, are prepd. Thus, 0.29 g 2-hydroxyquinoline was dissolved in DMF and treated with 80 mg NaH at 60.degree. for 30 min with stirring followed by cooling the reaction mixt. to room temp. and adding 2.16 g 1,4-dibromobutane and the resulting mixt. was stirred at 60.degree. for 4 h to give 64% 1-(4-bromobutyl)-2(1H)-quinolinone (II). II 0.56, 3-(1-piperazinyl)-1,2-benzisothiazole 0.44, and  $K_2CO_3$  0.33 g were suspended in DMF and stirred at room temp. for 12 h to give 80% title compd. I ( $n = 4$ ,  $W = 2$ -oxo-1,2-dihydro-1-quinolinyl). II ( $n = 4$ ,  $W = 9$ -carbazolyl) and II ( $n = 3$ ,  $W = 2$ -oxo-1,2-dihydro-1-quinolinyl) showed  $ED_{50}$  of 1.15 and 0.92 mg/kg i.p., resp., for inhibiting methamphetamine-induced spontaneous movement of mice (vs. 0.16 and 1.05

mg/kg i.p. for haloperidol and chlorpromazine, resp.) and induced catalepsy in mice at ED50 of >100 and 83.3 mg/kg i.p. in mice (vs. 1.3 and 6.2 mg/kg i.p. for haloperidol and chlorpromazine, resp.).


IT **165109-31-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of [N-(heterocyclalkyl)piperazinyl]benzisothiazole derivs. as antipsychotics)

RN 165109-31-9 CAPLUS

CN 2(1H)-Quinolinone, 1-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L8 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:657604 CAPLUS

DN 123:55870

TI Preparation of indazole derivatives as antipsychotics

IN Sasaki, Toshiro; Nakatani, Juko; Hiranuma, Toyoichi; Kashima, Hiroko; Fukuda, Yoshimasa

PA Meiji Seika Co, Japan

SO Jpn. Kokai Tokkyo Koho, 23 pp.



CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 07033744	A2	19950203	JP 1993-204612	19930727
PRAI	JP 1993-204612		19930727		
OS	MARPAT 123:55870				
GI					




AB The title compds. I [ $n = 2 - 6$ ;  $V = H, \text{halo}$ ;  $R_1 = H, \text{alkyl, etc.}$ ;  $W = \text{heterocycle}$  (further details on said heterocycle are given)] are prepd. Indazole deriv. II (prepn. given) showed ED50 of 0.50 mg/Kg i.p. against methamphetamine-induced activities in mice, vs. ED50 of 0.16 mg/Kg i.p. shown by haloperidol. In a test for catalepsy-causing activity in mice, II showed ED50 of 18 mg/Kg i.p., vs. ED50 of 1.3 mg/Kg i.p. shown by haloperidol.

IT **164519-46-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of indazole derivs. as antipsychotics)

RN 164519-46-4 CAPLUS

CN 6(5H)-Phenanthridinone, 5-[4-[4-(1H-indazol-3-yl)-1-piperazinyl]butyl]-  
(9CI) (CA INDEX NAME)



L8 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:464322 CAPLUS


DN 122:214060

TI Preparation of [(benzisothiazolylpiperazinyl)butyl]pyridinecarboxamides and related compounds as antipsychotics.

IN Norman, Mark Henry; Navas, Frank, III

PA Wellcome Foundation Ltd., UK  
 SO PCT Int. Appl., 59 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9418196	A1	19940818	WO 1994-GB265	19940210
	W: AU, BG, CA, CN, CZ, FI, HU, JP, KR, NZ, RO, RU, SK, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	ZA 9400891	A	19950810	ZA 1994-891	19940209
	CA 2155758	AA	19940818	CA 1994-2155758	19940210
	AU 9460051	A1	19940829	AU 1994-60051	19940210
	EP 683778	A1	19951129	EP 1994-906290	19940210
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1117731	A	19960228	CN 1994-191142	19940210
	JP 08506337	T2	19960709	JP 1994-517819	19940210
	HU 73654	A2	19960930	HU 1995-1881	19940210
	FI 9503777	A	19950809	FI 1995-3777	19950809
PRAI	GB 1993-2622	A	19930210		
	WO 1994-GB265	W	19940210		
OS	MARPAT 122:214060				
GI					



AB Title compds. [I; Y = heteroaryl group optionally substituted by .gtoreq.1 halo, nitro, alkyl, alkoxy, aryloxy, arylalkylenoxy, OH, SOnR2 or SOnN(R2)2, CN, CON(R2)2, COR2, CO2R2, CO-aryl, azido, N(R2)2, NR2N(R2a)2, NR2N:C(R2a)2, NR2(C:O)CH(N(R2a)2)R2b, NR2(C:O)R2a, NR2CO2R2a, alkoxy, carbonylamino, PhN:N; with the proviso that Y does not include benzisothiazolyis or benzisoxazolyis; n = 0-2; V = O, S; Z = alkylene optionally interrupted by O, SOn, alkenylene, alkynylene; X = N, CR3, COR3; A = CR4, N; B = O, NR5, SOn; R1 = H, halo, NO2, cyano, N(R6)2, alkoxy, aryloxy, arylalkenyloxy, COR6; R, R2, R2a, R2B, R3, R4, R5, R6 = H, alkyl], and salts, solvates, N-oxides, and physiol. functional derivs. thereof, were prepd. Thus, 3-[4-(4-aminobutyl)-1-piperazinyl]-1,2-benzisothiazole (prepn. given) in CHCl3 was treated with Me3Al and then with Me 3-amino-2-thiophenecarboxylate; the mixt. was heated at 45-50.degree. for 5 days to give 3-amino-N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-2-thiophenecarboxamide, isolated as the hydrochloride. The latter antagonized apomorphine-induced climbing in mice with ED50 = 9.7 mg/kg orally.


IT 161940-16-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of [(benzisothiazolylpiperazinyl)butyl]pyridinecarboxamides and  
 related compds. as antipsychotics)

RN 161940-16-5 CAPLUS

CN 8-Quinolinecarboxamide, N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1991:492295 CAPLUS

DN 115:92295

TI Preparation of heteroarylpiperazines as antipsychotic agents

IN Howard, Harry R.

PA Pfizer Inc., USA

SO Eur. Pat. Appl., 20 pp.




CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 409435	A1	19910123	EP 1990-307166	19900629
	EP 409435	B1	19941026		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 9100863	A1	19910124	WO 1989-US2954	19890707
	W: FI, HU, NO, RO, SU, US				
	ES 2062374	T3	19941216	ES 1990-307166	19900629
	JP 03044388	A2	19910226	JP 1990-176120	19900703
	JP 07017633	B4	19950301		
	CA 2020611	AA	19910108	CA 1990-2020611	19900706
	US 5350747	A	19940927	US 1992-836019	19920220
PRAI	WO 1989-US2954	A	19890707		
OS	MARPAT 115:92295				
GI					




AB The title compds. [I; W1 = CR2R3; W2 = CR4R5; W3 = CR6R7; 1 of W1-W3 may be absent; R1 = (substituted) benzisoxazolyl, benzisothiazolyl, benzopyrazolyl; R2-R7 = H, alkyl, 2 of them may form alkylene, alkenylene; X1 = H, halo, C1-4 alkyl, alkoxy, NO2, cyano, etc.; Y1 = H, C1-4 alkyl, (substituted) Ph, etc.; X1Y1 = heterocyclyl; Z = C1-6 alkylene], useful as antipsychotic agents (no data), were prepd. A mixt. of piperazine deriv. II, quinolinone III (prepn. given), Na2CO3, and KI in MIBK was heated at 90.degree. under N to give 13% title compd. IV, sepd. as HCl.1/2 H2O. Also prepd. were 17 addnl. I and numerous intermediates.

IT **133999-10-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as antipsychotic agent)

RN 133999-10-7 CAPLUS

CN 2(1H)-Quinolinone, 7-chloro-3,4-dihydro-6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4,4-dimethyl- (9CI) (CA INDEX NAME)



=> d 18 4 5 12 bib abs hitstr


L8 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN



AN 2004:287843 CAPLUS  
 DN 140:321381  
 TI Preparation of heterocyclic substituted piperazines for the treatment of schizophrenia  
 IN Davis, Jamie Marie; Gregory, Tracy Fay; Walters, Michael Anthony  
 PA Warner-Lambert Company LLC, USA  
 SO PCT Int. Appl., 90 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

App<sup>3</sup>

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004029048	A1	20040408	WO 2003-IB4113	20030918
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2500115	AA	20040408	CA 2003-2500115	20030918
	EP 1546145	A1	20050629	EP 2003-798314	20030918
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003014796	A	20050726	BR 2003-14796	20030918
	US 2004067960	A1	20040408	US 2003-672949	20030926
PRAI	US 2002-413839P	P	20020926		
	WO 2003-IB4113	W	20030918		
OS	MARPAT 140:321381				
GI					



AB The title compds. [I; Ar = 1,2-benzisothiazoyl, 1,2-benzisothiazoyl-1-oxide, naphthyl, pyridyl, etc.; with the proviso that Ar can not be attached to the piperazine ring via a Ph ring of Ar; Y = N, CH; A = (CH<sub>2</sub>)<sub>n</sub>CH<sub>2</sub> (wherein n = 1-4, one of the CH<sub>2</sub> groups that is not adjacent to the piperazine nitrogen can be replaced by an oxygen atom); R<sub>2</sub>, R<sub>3</sub> = H, alkyl, fluoroalkyl, alkoxy, etc.; Q = (un)satd. (un)substituted 5-7 membered monocyclic heterocyclic ring contg. 1-3 heteroatoms selected from O, N and S], useful in the treatment of central nervous system disorders, were prepd. Thus, reacting 3-methylbut-2-enoic acid (2-{2-[4-(1,2-benzisothiazol-3-yl)-piperazin-1-yl]ethyl}phenyl)amide (prepn. given) with AlCl<sub>3</sub> in C<sub>6</sub>H<sub>5</sub>Cl afforded 8-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-

yl]ethyl}-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one which showed  $K_i$  of .1 to req. 1  $\mu$ M against dopamine D2 receptor binding, and  $K_i$  of .1 to req. 1  $\mu$ M against 5-HT<sub>2A</sub> receptor binding. The pharmaceutical compn. comprising the compd. I is claimed.

IT 677708-42-8P 677708-43-9P 677708-44-0P


677708-45-1P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclic substituted piperazines for the treatment of schizophrenia)


RN 677708-42-8 CAPLUS

CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-benzoyl-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)





RN 677708-43-9 CAPLUS

CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(3-methoxybenzoyl)-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 677708-44-0 CAPLUS

CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(2,5-dimethoxybenzoyl)-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-45-1 CAPLUS

CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(cyclohexylcarbonyl)-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




IT 677708-40-6P

RL: CRT (Combinatorial reactant); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(prepn. of heterocyclic substituted piperazines for the treatment of schizophrenia)

RN 677708-40-6 CAPLUS

CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




IT 677708-34-8P 677708-39-3P 677708-48-4P  
 677708-49-5P 677708-51-9P 677708-53-1P  
 677708-58-6P 677708-86-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (prepn. of heterocyclic substituted piperazines for the treatment of schizophrenia)

RN 677708-34-8 CAPLUS


CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 677708-39-3 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-phenyl- (9CI) (CA INDEX NAME)




RN 677708-48-4 CAPLUS

CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-fluoro-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 677708-49-5 CAPLUS

CN 2(1H)-Quinolinone, 6-fluoro-8-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 677708-51-9 CAPLUS

CN 2(1H)-Quinolinone, 8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 677708-53-1 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,5-trimethyl- (9CI) (CA INDEX NAME)




RN 677708-58-6 CAPLUS

CN Quinoline, 8-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 677708-86-0 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-fluoro-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




IT 677708-35-9P 677708-36-0P 677708-37-1P  
 677708-38-2P 677708-41-7P 677708-46-2P  
 677708-47-3P 677708-50-8P 677708-52-0P  
 677708-54-2P 677708-55-3P 677708-56-4P  
 677708-57-5P 677708-59-7P 677708-60-0P  
 677708-61-1P 677708-62-2P 677708-63-3P  
 677708-64-4P 677708-65-5P 677708-66-6P  
 677708-67-7P 677708-68-8P 677708-69-9P  
 677708-70-2P 677708-71-3P 677708-92-8P  
 677708-93-9P 677708-94-0P 677708-95-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(prepn. of heterocyclic substituted piperazines for the treatment of  
 schizophrenia)


RN 677708-35-9 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,4,4-trimethyl- (9CI) (CA INDEX NAME)



RN 677708-36-0 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-fluoro-3,4-dihydro-4,4-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 677708-37-1 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)






● x HCl


RN 677708-38-2 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)





RN 677708-41-7 CAPLUS

CN Quinoline, 1-acetyl-8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 677708-46-2 CAPLUS

CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI)  
(CA INDEX NAME)




RN 677708-47-3 CAPLUS

CN 2(1H)-Quinolinone, 6-fluoro-3,4-dihydro-4,4-dimethyl-8-[2-[4-(1-oxido-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 677708-50-8 CAPLUS


CN Quinoline, 1-acetyl-6-fluoro-8-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4,4-dimethyl-, hydrochloride (9CI)  
(CA INDEX NAME)



● x HCl

RN 677708-52-0 CAPLUS


CN Quinoline, 1-acetyl-8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,4-tetrahydro-4,4-dimethyl-, hydrochloride (9CI)  
(CA INDEX NAME)



●x HCl

RN 677708-54-2 CAPLUS


CN Quinoline, 1-acetyl-8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4,4,5-trimethyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 677708-55-3 CAPLUS


CN Quinoline, 1-acetyl-8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 677708-56-4 CAPLUS

CN Quinoline, 1-acetyl-8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-fluoro-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 677708-57-5 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 677708-59-7 CAPLUS


CN Quinoline, 1-acetyl-8-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4,4,5-trimethyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 677708-60-0 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-6-fluoro-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-61-1 CAPLUS


CN Quinoline, 1-acetyl-8-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-6-fluoro-1,2,3,4-tetrahydro-4,4-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 677708-62-2 CAPLUS

CN 2-(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 677708-63-3 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-64-4 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-ethyl- (9CI) (CA INDEX NAME)






10/672949


RN 677708-65-5 CAPLUS

CN 4H-Cyclopenta[c]quinolin-4-one, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 677708-66-6 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3-ethyl-4-methyl- (9CI) (CA INDEX NAME)



RN 677708-67-7 CAPLUS


CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-propyl- (9CI) (CA INDEX NAME)



10/672949


RN 677708-68-8 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 677708-69-9 CAPLUS

CN 6(5H)-Phenanthridinone, 4-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 677708-70-2 CAPLUS


CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 677708-71-3 CAPLUS


10/672949

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 677708-92-8 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 677708-93-9 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 677708-94-0 CAPLUS

CN 2(1H)-Quinolinone, 8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-6-chloro-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 677708-95-1 CAPLUS

CN 2(1H)-Quinolinone, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



IT 677708-81-5P 677708-82-6P 677708-83-7P


**677708-84-8P 677708-85-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of heterocyclic substituted piperazines for the treatment of schizophrenia)


RN 677708-81-5 CAPLUS

CN Quinoline, 6-fluoro-8-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 677708-82-6 CAPLUS

CN Quinoline, 8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 677708-83-7 CAPLUS

CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4,4,5-trimethyl- (9CI) (CA INDEX NAME)




RN 677708-84-8 CAPLUS

CN Quinoline, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-4-phenyl- (9CI) (CA INDEX NAME)



RN 677708-85-9 CAPLUS

CN Quinoline, 8-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-6-fluoro-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:267327 CAPLUS  
DN 140:287412  
TI Preparation of piperazines as dopamine D2 and serotonin 5HT2A receptors  
inhibitors for the treatment of central nervous system disorders, in  
particular schizophrenia  
IN Andreana, Tonja Lynn; Cho, Stephen Sung Yong; Graham, James Michael;  
Gregory, Tracy Fay; Howard, Harry Ralph, Jr.; Kornberg, Brian Edward;  
Nikam, Sham Shridhar; Pflum, Derek Andrew  
PA Warner-Lambert Company LLC, USA  
SO PCT Int. Appl., 158 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026864	A1	20040401	WO 2003-IB3902	20030905
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
	PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,				
	TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2499326	AA	20040401	CA 2003-2499326	20030905
	EP 1546143	A1	20050629	EP 2003-797433	20030905
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003014393	A	20050719	BR 2003-14393	20030905
	US 2004138230	A1	20040715	US 2003-660908	20030912
PRAI	US 2002-411475P	P	20020917		
	US 2002-416355P	P	20021004		
	WO 2003-IB3902	W	20030905		
OS	MARPAT 140:287412				

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [wherein X = S, O, SO, SO<sub>2</sub>, CH<sub>2</sub>, NH and derivs.; Y, Z = independently N or CH; A = (CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>, (CH<sub>2</sub>)<sub>m</sub>O, (CH<sub>2</sub>)<sub>m</sub>NR<sub>9</sub>, (CH<sub>2</sub>)<sub>m</sub>C(R<sub>7</sub>R<sub>8</sub>); R<sub>7</sub>, R<sub>8</sub> = independently (un)substituted alkyl, alkoxy, or CR<sub>7</sub>R<sub>8</sub> = carbonyl; m = 1-4; R<sub>4</sub>, R<sub>5</sub> = independently H, (un)substituted alkyl, alkoxy, or when X = NR<sub>6</sub> and derivs., CR<sub>4</sub>R<sub>5</sub>R<sub>6</sub>N = 4-7 membered heterocyclcyl ring, with the proviso that when R<sub>9</sub>R<sub>4</sub> or R<sub>9</sub>R<sub>5</sub> = a ring, the other of R<sub>4</sub> and R<sub>5</sub> is absent; R<sub>9</sub> = H, (un)substituted alkyl, alkoxy; R<sub>6</sub> = H, (un)substituted alkyl, alkoxy; R<sub>1</sub> = H, (un)substituted alkyl; R<sub>2</sub>, R<sub>3</sub> = independently H, halo, hetero/aryl, (un)substituted aryl/heteroarylalkyl, alkoxy, etc.; V, W = independently CH<sub>2</sub> and derivs. or CH and derivs.; and their pharmaceutically acceptable salts] were prepd. s dopamine D<sub>2</sub> and serotonin 5HT<sub>2A</sub> receptors inhibitors for treating central nervous system disorders, in particular schizophrenia (no data). For example, II.bul.MeSO<sub>3</sub>H was prepd. by acylation of 3-chloro-2-methylaniline with 3,3-diethylacryloyl chloride, one-pot Friedel-Craft alkylation with chloroacetyl chloride and cyclization in the presence of AlCl<sub>3</sub> to chloroacetylquinoline intermediate, redn. to chloroethylquinoline III, alkylation of 3-(piperazin-1-yl)benzo[d]isothiazole hydrochloride with III, followed by salt formation of II with methanesulfonic acid. II acted as dopamine D<sub>2</sub> and serotonin 5HT<sub>2A</sub> receptors inhibitors with a K<sub>i</sub> value of 0.9 nM and 1 nM, resp. Thus, I and their formulations are useful for treating central nervous system disorders, in particular schizophrenia and depression.

IT **676117-35-4P**, 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetamide  
**676117-36-5P**, 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]propionamide  
**676117-37-6P**, 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]-N-phenylpropionamide **676117-38-7P**, [6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetic acid ethyl ester **676117-39-8P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3-methyl-3,4-dihydro-1H-quinolin-2-one **676117-40-1P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-1-(2-oxo-2-phenylethyl)-3,4-dihydro-1H-quinoline-2-one **676117-41-2P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(2-methoxyethyl)-3-methyl-3,4-dihydro-1H-quinolin-2-one **676117-42-3P**, 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]propionitrile **676117-43-4P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-isobutyl-3-methyl-3,4-dihydro-1H-quinolin-2-one **676117-44-5P**, 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetamide **676117-45-6P**, [6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetic acid ethyl ester **676117-46-7P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676117-47-8P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-1-(2-oxo-2-phenylethyl)-3,4-dihydro-1H-quinolin-2-one **676117-48-9P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(methoxymethyl)-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676117-49-0P**,




6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(2-methoxyethyl)-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676117-50-3P**,  
 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]propionitrile **676117-51-4P**,  
 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-ethyl-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676117-52-5P**,  
 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-isobutyl-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676117-53-6P**,  
 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]propionamide **676117-54-7P**,  
 2-[6-[2-[4-(1,2-Benzoisothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]-N-phenylpropionamide **676117-55-8P**,  
 [6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetic acid ethyl ester **676117-56-9P**,  
 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-4-methyl-3,4-dihydro-1H-quinolin-2-one **676117-57-0P**,  
 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-1-(2-oxo-2-phenylethyl)-3,4-dihydro-1H-quinolin-2-one **676117-58-1P**,  
 2-[6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]propionitrile **676117-59-2P**,  
 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-ethyl-4-methyl-3,4-dihydro-1H-quinolin-2-one **676117-60-5P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-1-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-quinolin-2-one **676117-61-6P**,  
 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-isobutyl-4-methyl-3,4-dihydro-1H-quinolin-2-one **676117-62-7P**, 2-[6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetamide **676117-63-8P**, 2-[6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]propionamide **676117-64-9P**, 2-[6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]-N-phenylpropionamide **676117-65-0P**,  
 [6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetic acid ethyl ester **676117-66-1P**,  
 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-4-methyl-3,4-dihydro-1H-quinolin-2-one **676117-67-2P**,  
 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1-(2-methoxyethyl)-4-methyl-3,4-dihydro-1H-quinolin-2-one **676117-68-3P**,  
 2-[6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]propionitrile **676117-69-4P**,  
 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1-ethyl-4-methyl-3,4-dihydro-1H-quinolin-2-one **676117-70-7P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1-isobutyl-4-methyl-3,4-dihydro-1H-quinolin-2-one **676117-71-8P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dimethyl-1H-quinolin-2-one **676117-72-9P**,  
 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-[2-(2-hydroxyethoxy)ethyl]-3,4-dimethyl-1H-quinolin-2-one **676117-73-0P**,  
 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(2-methoxyethyl)-3,4-dimethyl-1H-quinolin-2-one **676117-74-1P**,  
 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-ethyl-3,4-dimethyl-1H-quinolin-2-one **676117-75-2P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1-(2,2,2-trifluoroethyl)-1H-quinolin-2-one **676117-76-3P**,  
 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-isobutyl-3,4-dimethyl-1H-quinolin-2-one **676117-77-4P**, 2-[6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-2-oxo-2H-quinolin-1-yl]acetamide **676117-78-5P**, 2-[6-[2-[4-

(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-2-oxo-2H-quinolin-1-yl]propionamide **676117-79-6P**, [6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-2-oxo-2H-quinolin-1-yl]acetic acid ethyl ester **676117-80-9P**, 2-[6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-2-oxo-2H-quinolin-1-yl]propionic acid methyl ester **676117-81-0P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dimethyl-1H-quinolin-2-one **676117-82-1P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1-(2-oxo-2-phenylethyl)-1H-quinolin-2-one **676117-83-2P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1-(2-methoxyethyl)-3,4-dimethyl-1H-quinolin-2-one **676117-84-3P**, 2-[6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-2-oxo-2H-quinolin-1-yl]propionitrile **676117-85-4P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1-ethyl-3,4-dimethyl-1H-quinolin-2-one **676117-86-5P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1-(2,2,2-trifluoroethyl)-1H-quinolin-2-one **676117-87-6P**, [6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl]acetic acid ethyl ester **676117-88-7P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-1-pentyl-3,4-dihydro-1H-quinolin-2-one **676117-89-8P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-1-(3-methylbutyl)-3,4-dihydro-1H-quinolin-2-one **676117-90-1P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(2-ethylbutyl)-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-91-2P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(2-ethoxyethyl)-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-92-3P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(2,2-dimethylpropyl)-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-93-4P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-cyclohexylmethyl-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-94-5P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-cyclobutylmethyl-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-95-6P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-isobutyl-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-96-7P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-(n-butyl)-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-97-8P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-cyclobutyl-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one  
 RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of piperazines for treating of central nervous system disorders, in particular schizophrenia)


RN 676117-35-4 CAPLUS

CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 676117-36-5 CAPLUS

CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,3-dimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 676117-37-6 CAPLUS

CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,3-dimethyl-2-oxo-N-phenyl- (9CI) (CA INDEX NAME)




RN 676117-38-7 CAPLUS

CN 1(2H)-Quinolineacetic acid, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 676117-39-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dihydro-3-methyl- (9CI) (CA INDEX NAME)




RN 676117-40-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(2-oxo-2-phenylethyl)-3,4-dihydro-3-methyl- (9CI) (CA INDEX NAME)




RN 676117-41-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(2-methoxyethyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 676117-42-3 CAPLUS

CN 1(2H)-Quinolineacetonitrile, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,3-dimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 676117-43-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 676117-44-5 CAPLUS

CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3-dimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 676117-45-6 CAPLUS

CN 1(2H)-Quinolineacetic acid, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3-dimethyl-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 676117-46-7 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)




RN 676117-47-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(2-oxo-2-phenylethyl)-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)




RN 676117-48-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1-(methoxymethyl)-3,3-dimethyl- (9CI) (CA INDEX NAME)




RN 676117-49-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1-(2-methoxyethyl)-3,3-dimethyl- (9CI) (CA INDEX NAME)




RN 676117-50-3 CAPLUS

CN 1(2H)-Quinolineacetonitrile, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,3,3-trimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 676117-51-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-ethyl-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-52-5 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3-dimethyl-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 676117-53-6 CAPLUS


CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,4-dimethyl-2-oxo- (9CI) (CA INDEX NAME)






RN 676117-54-7 CAPLUS

CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,4-dimethyl-2-oxo-N-phenyl- (9CI)  
(CA INDEX NAME)




RN 676117-55-8 CAPLUS

CN 1(2H)-Quinolineacetic acid, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 676117-56-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 676117-57-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-1-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 676117-58-1 CAPLUS

CN 1(2H)-Quinolineacetonitrile, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,4-dimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 676117-59-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-ethyl-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 676117-60-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 676117-61-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 676117-62-7 CAPLUS


CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-2-oxo- (9CI) (CA INDEX NAME)



10/672949


RN 676117-63-8 CAPLUS

CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,4-dimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 676117-64-9 CAPLUS

CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,4-dimethyl-2-oxo-N-phenyl- (9CI) (CA INDEX NAME)




RN 676117-65-0 CAPLUS

CN 1(2H)-Quinolineacetic acid, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 676117-66-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 676117-67-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1-(2-methoxyethyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 676117-68-3 CAPLUS

CN 1(2H)-Quinolineacetonitrile, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-.alpha.,4-dimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 676117-69-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-1-ethyl-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 676117-70-7 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 676117-71-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-72-9 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-[2-(2-hydroxyethoxy)ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



10/672949


RN 676117-73-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(2-methoxyethyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676117-74-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-ethyl-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676117-75-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 676117-76-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 676117-77-4 CAPLUS

CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676117-78-5 CAPLUS


CN 1(2H)-Quinolineacetamide, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-.alpha.,3,4-trimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676117-79-6 CAPLUS


CN 1(2H)-Quinolineacetic acid, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)






RN 676117-80-9 CAPLUS

CN 1(2H)-Quinolineacetic acid, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-.alpha.,3,4-trimethyl-2-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 676117-81-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676117-82-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-1-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 676117-83-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-1-(2-methoxyethyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676117-84-3 CAPLUS

CN 1(2H)-Quinolineacetonitrile, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-.alpha.,3,4-trimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 676117-85-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-1-ethyl-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676117-86-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 676117-87-6 CAPLUS

CN 1(2H)-Quinolineacetic acid, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 676117-88-7 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-1-pentyl- (9CI) (CA INDEX NAME)




RN 676117-89-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-1-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 676117-90-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(2-ethylbutyl)-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)




RN 676117-91-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(2-ethoxyethyl)-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)




RN 676117-92-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(2,2-dimethylpropyl)-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)




RN 676117-93-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(cyclohexylmethyl)-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)




RN 676117-94-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-(cyclobutylmethyl)-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)




RN 676117-95-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 676117-96-7 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-butyl-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676117-97-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-cyclobutyl-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



IT 676115-67-6P, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one 676115-82-5P


676117-11-6P, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one

RL: CRT (Combinatorial reactant); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; prepn. of piperazines for treating of central nervous system disorders, in particular schizophrenia)


RN 676115-67-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 676115-82-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-11-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




IT 676116-01-1P, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one  
 676116-05-5P, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-7-chloro-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one  
 676116-14-6P, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-7-fluoro-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one  
 676116-82-8P, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-7-fluoro-1,4,4-trimethyl-3,4-dihydro-1H-quinolin-2-one  
 676116-91-9P, 1-[6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-3,3-dimethyl-3,4-dihydro-2H-quinolin-1-yl]ethanone  
 676116-95-3P, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-1,3,3-trimethyl-1,2,3,4-tetrahydroquinoline  
 676117-13-8P, 8-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1,2,3,5-tetrahydrocyclopenta[c]quinolin-4-one  
 676118-30-2P, 8-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propoxy]-1,2,3,5-tetrahydrocyclopenta[c]quinolin-4-one  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; prepn. of piperazines for treating of central nervous

system disorders, in particular schizophrenia)


RN 676116-01-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)




RN 676116-05-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-chloro-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)




RN 676116-14-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-fluoro-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-82-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-7-fluoro-3,4-dihydro-1,4,4-trimethyl- (9CI) (CA INDEX NAME)






10/672949


RN 676116-91-9 CAPLUS

CN Quinoline, 1-acetyl-6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,4-tetrahydro-3,3-dimethyl- (9CI) (CA INDEX NAME)




RN 676116-95-3 CAPLUS

CN Quinoline, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,4-tetrahydro-1,3,3-trimethyl- (9CI) (CA INDEX NAME)




RN 676117-13-8 CAPLUS

CN 4H-Cyclopenta[c]quinolin-4-one, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 676118-30-2 CAPLUS

CN 4H-Cyclopenta[c]quinolin-4-one, 8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propoxy]-1,2,3,5-tetrahydro- (9CI) (CA INDEX NAME)



IT 134017-32-6P, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one 676115-68-7P

676115-69-8P 676115-70-1P 676115-72-3P,

6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1,4-dimethyl-3,4-

dihydro-1H-quinolin-2-one **676115-73-4P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676115-74-5P** **676115-77-8P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one **676115-78-9P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676115-79-0P** **676115-85-8P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1,3,3,4,4-pentamethyl-3,4-dihydro-1H-quinolin-2-one **676115-88-1P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,3,4-trimethyl-3,4-dihydro-1H-quinolin-2-one **676115-92-7P**, 6-[2-[4-(1H-Indazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one **676115-94-9P**, 6-[2-[4-(1H-Indazol-3-yl)piperazin-1-yl]ethyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676115-95-0P**, 6-[2-[4-(1H-Indazol-3-yl)piperazin-1-yl]ethyl]-1,4,4-trimethyl-3,4-dihydro-1H-quinolin-2-one **676115-96-1P**, 6-[2-[4-(1H-Indazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one **676115-97-2P**, 6-[2-[4-(1H-Indazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676115-98-3P**, 6-[2-[4-(1H-Indazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676115-99-4P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1,3,3,4,4-pentamethyl-3,4-dihydro-1H-quinolin-2-one hydrochloride **676116-00-0P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3,4-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-04-4P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one mesylate **676116-06-6P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-7-chloro-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one methanesulfonate **676116-10-2P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-7-fluoro-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one hydrochloride **676116-15-7P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-7-fluoro-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one methanesulfonate **676116-16-8P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-8-ethyl-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-20-4P** **676116-24-8P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-8-ethyl-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-25-9P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-26-0P**, 6-[2-[4-(5-Methoxybenzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-28-2P**, 6-[2-[4-(7-Methoxybenzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-29-3P**, 6-[2-[4-(5-Fluorobenzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-31-7P**, 6-[2-[4-(5-Fluorobenzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-33-9P**, 6-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-34-0P**, 6-[2-[4-(5-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-35-1P**, 6-[2-[4-(7-Fluorobenzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-37-3P**, 6-[2-[4-(6-Methylbenzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-39-5P**, 6-[2-[4-(6-Fluorobenzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676116-40-8P**, 6-[2-[4-(5-Fluorobenzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1,4,4,8-tetramethyl-3,4-dihydro-1H-quinolin-2-one

hydrochloride **676116-41-9P**, 1-Ethyl-6-[2-[4-(5-fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one hydrochloride **676116-42-0P**, 6-[2-[4-(5-Fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-1-(n-propyl)-3,4-dihydro-1H-quinolin-2-one hydrochloride **676116-43-1P**, 6-[2-[4-(5-Fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-isopropyl-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one hydrochloride **676116-44-2P**, 6-[2-[4-(5-Fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1-methoxymethyl-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one hydrochloride **676116-45-3P**, 1-(2-Ethoxyethyl)-6-[2-[4-(5-fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one hydrochloride **676116-52-2P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-55-5P**, 6-[3-[4-(1H-Indazol-3-yl)piperazin-1-yl]propyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-56-6P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-7-chloro-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-59-9P**, 6-[3-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]propyl]-7-chloro-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-60-2P**, 6-[3-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]propyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one **676116-61-3P**, 6-[3-[4-(1H-Indazol-3-yl)piperazin-1-yl]propyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one **676116-62-4P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-65-7P**, 6-[3-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]propyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-66-8P**, 6-[3-[4-(1H-Indazol-3-yl)piperazin-1-yl]propyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-67-9P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one **676116-70-4P**, 6-[3-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]propyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one **676116-71-5P**, 6-[3-[4-(1H-Indazol-3-yl)piperazin-1-yl]propyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one **676116-72-6P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-(4S)-methyl-3,4-dihydro-1H-quinolin-2-one **676116-74-8P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-(4R)-methyl-3,4-dihydro-1H-quinolin-2-one **676116-76-0P**, **676116-77-1P** **676116-78-2P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-7-fluoro-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676116-84-0P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-7-fluoro-1,4,4-trimethyl-3,4-dihydro-1H-quinolin-2-one mesylate **676116-85-1P**, 1-[6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-7-fluoro-4,4-dimethyl-3,4-dihydro-2H-quinolin-1-yl]ethanone **676116-88-4P**, 1-[6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-4,4-dimethyl-3,4-dihydro-2H-quinolin-1-yl]ethanone **676116-94-2P**, 1-[6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-3,3-dimethyl-3,4-dihydro-2H-quinolin-1-yl]ethanone mesylate **676116-97-5P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-1,3,3-trimethyl-1,2,3,4-tetrahydroquinoline mesylate **676116-98-6P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-8-chloro-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676117-01-4P**, 6-[3-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]propyl]-8-chloro-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one **676117-02-5P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-05-8P**, 6-[3-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]propyl]-4,4,8-trimethyl-3,4-dihydro-1H-quinolin-2-one **676117-06-9P**, 6-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-8-ethyl-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one


**676117-09-2P**, 6-[3-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]propyl]-8-ethyl-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one  
**676117-10-5P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-1H-quinolin-2-one **676117-12-7P**,  
 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-ethyl-1H-quinolin-2-one **676117-14-9P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-ethyl-4-methyl-1H-quinolin-2-one **676117-15-0P**,  
 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-(n-propyl)-1H-quinolin-2-one **676117-16-1P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-isopropyl-1H-quinolin-2-one  
**676117-17-2P**, 2-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-7,8,9,10-tetrahydro-5H-phenanthridin-6-one **676117-18-3P**,  
 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-trifluoromethyl-1H-quinolin-2-one **676117-19-4P**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-phenyl-1H-quinolin-2-one **676117-20-7P**,  
 9-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one **676117-23-0P**,  
 9-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1,1-dimethyl-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one hydrochloride  
**676117-27-4P**, 8-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-6,6-dimethyl-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one hydrochloride **676117-98-9P**, 6-[2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one  
**676117-99-0P**, 6-[2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one **676118-01-7P**,  
 6-[2-[4-(5-Chloro-benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one **676118-02-8P**, 6-[2-[4-(5-Methoxy-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one **676118-03-9P**, 6-[2-[4-(7-Fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one  
**676118-05-1P**, 6-[2-[4-(6-Fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one **676118-06-2P**,  
 6-[2-[4-(5-Fluoro-benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one **676118-09-5P**, 6-[2-[4-(1H-Indazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one  
**676118-10-8P**, 8-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-6-methyl-3,5-dihydro-1H-furo[3,4-c]quinolin-4-one  
**676118-15-3P**, 8-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,5-dihydro-1H-furo[3,4-c]quinolin-4-one **676118-17-5P**,  
 8-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-3,5-dihydro-1H-furo[3,4-c]quinolin-4-one **676118-19-7P**, 8-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-3,5-dihydro-1H-furo[3,4-c]quinolin-4-one **676118-23-3P**, 8-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-2-methyl-1,2,3,5-tetrahydropyrrolo[3,4-c]quinolin-4-one **676118-27-7P**, 8-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-2-methyl-1,2,3,5-tetrahydropyrrolo[3,4-c]quinolin-4-one **676118-28-8P**, 8-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-5-ethyl-1,2,3,5-tetrahydrocyclopenta[c]quinolin-4-one  
**676118-29-9P**, 8-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-5-methyl-1,2,3,5-tetrahydrocyclopenta[c]quinolin-4-one  
**676118-31-3P**, 8-[3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]propoxy]-1,2,3,5-tetrahydrocyclopenta[c]quinolin-4-one methanesulfonate  
**676118-34-6P**, 6-[2-[4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl]ethyl]-1,4,4-trimethyl-3,4-dihydro-1H-quinolin-2-one **676118-35-7P**,  
 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-1,3,3,4,4-pentamethyl-3,4-dihydro-1H-quinolin-2-one  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

## (Uses)

(drug candidate; prepn. of piperazines for treating of central nervous system disorders, in particular schizophrenia)

RN 134017-32-6 CAPLUS


CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 676115-68-7 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 676115-69-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



10/672949

RN 676115-70-1 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-  
3,4-dihydro-1,4-dimethyl-, hydrochloride (10:11) (9CI) (CA INDEX NAME)



●11/10 HCl


RN 676115-72-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-  
3,4-dihydro-1,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676115-73-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-  
3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676115-74-5 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-  
3,4-dihydro-1,4,4-trimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 676115-77-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl- (9CI) (CA INDEX NAME)




RN 676115-78-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 676115-79-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl




RN 676115-85-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,3,3,4,4-pentamethyl- (9CI) (CA INDEX NAME)




RN 676115-88-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3,4-trimethyl- (9CI) (CA INDEX NAME)




RN 676115-92-7 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 676115-94-9 CAPLUS


CN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-4,4-dimethyl- (9CI) (CA INDEX NAME)



10/672949


RN 676115-95-0 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-1,4,4-trimethyl- (9CI) (CA INDEX NAME)




RN 676115-96-1 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 676115-97-2 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 676115-98-3 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676115-99-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,3,3,4,4-pentamethyl-, monohydrochloride (9CI) (CA INDEX NAME)

10/672949


NAME)



● HCl

RN 676116-00-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3,4-trimethyl- (9CI) (CA INDEX NAME)




RN 676116-04-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-, mono(methanesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 676116-01-1


CMF C25 H30 N4 O S



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 676116-06-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-chloro-3,4-dihydro-4,4,8-trimethyl-, mono(methanesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 676116-05-5


CMF C25 H29 Cl N4 O S



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 676116-10-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-fluoro-3,4-dihydro-4,4,8-trimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 676116-15-7 CAPLUS  
 CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-fluoro-3,4-dihydro-4,4,8-trimethyl-, mono(methanesulfonate) (9CI) (CA INDEX NAME)


CM 1

CRN 676116-14-6  
 CMF C25 H29 F N4 O S




CM 2

CRN 75-75-2  
 CMF C H4 O3 S




RN 676116-16-8 CAPLUS  
 CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-8-ethyl-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-20-4 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-8-chloro-3,4-dihydro-4,4-dimethyl-, hydrochloride (5:6) (9CI) (CA INDEX NAME)



● 6/5 HCl


RN 676116-24-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-8-ethyl-3,4-dihydro-4,4-dimethyl-, hydrochloride (5:6) (9CI) (CA INDEX NAME)




RN 676116-25-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-, hydrochloride (5:6) (9CI) (CA INDEX NAME)




RN 676116-26-0 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(5-methoxy-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4,4,8-trimethyl- (9CI) (CA INDEX NAME)




RN 676116-28-2 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(7-methoxy-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4,4,8-trimethyl- (9CI) (CA INDEX NAME)




RN 676116-29-3 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-31-7 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(5-fluoro-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-33-9 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-

piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)




RN 676116-34-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(5-chloro-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)




RN 676116-35-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(7-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)



RN 676116-37-3 CAPLUS


CN 2(1H)-Quinolinone, 3,4-dihydro-4,4,8-trimethyl-6-[2-[4-(6-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 676116-39-5 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)





RN 676116-40-8 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,4,4,8-tetramethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 676116-41-9 CAPLUS


CN 2(1H)-Quinolinone, 1-ethyl-6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 676116-42-0 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 676116-43-1 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 676116-44-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1-(methoxymethyl)-4,4,8-trimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 676116-45-3 CAPLUS

CN 2(1H)-Quinolinone, 1-(2-ethoxyethyl)-6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,8-trimethyl-, monohydrochloride

10/672949


(9CI) (CA INDEX NAME)



● HCl


RN 676116-52-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676116-55-5 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-6-[3-[4-(1H-indazol-3-yl)-1-piperazinyl]propyl]-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-56-6 CAPLUS


CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-7-chloro-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-59-9 CAPLUS


CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-7-

chloro-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676116-60-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 676116-61-3 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-6-[3-[4-(1H-indazol-3-yl)-1-piperazinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 676116-62-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)




RN 676116-65-7 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)




RN 676116-66-8 CAPLUS

CN 2(1H)-Quinolinone, 3,4-dihydro-6-[3-[4-(1H-indazol-3-yl)-1-piperazinyl]propyl]-3,3-dimethyl- (9CI) (CA INDEX NAME)




RN 676116-67-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-3-methyl- (9CI) (CA INDEX NAME)




RN 676116-70-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-3-methyl- (9CI) (CA INDEX NAME)



RN 676116-71-5 CAPLUS


CN 2(1H)-Quinolinone, 3,4-dihydro-6-[3-[4-(1H-indazol-3-yl)-1-piperazinyl]propyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 676116-72-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676116-74-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676116-76-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676116-77-1 CAPLUS


CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676116-78-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-7-fluoro-3,4-dihydro-4,4-dimethyl-, (9CI) (CA INDEX NAME)




RN 676116-84-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-7-fluoro-3,4-dihydro-1,4,4-trimethyl-, mono(methanesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 676116-82-8


CMF C26 H31 F N4 O S



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 676116-85-1 CAPLUS

CN Quinoline, 1-acetyl-6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-7-fluoro-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-88-4 CAPLUS

CN Quinoline, 1-acetyl-6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,4-tetrahydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676116-94-2 CAPLUS




10/672949

CN Quinoline, 1-acetyl-6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,4-tetrahydro-3,3-dimethyl-, mono(methanesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 676116-91-9


CMF C27 H34 N4 O S



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 676116-97-5 CAPLUS

CN Quinoline, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,4-tetrahydro-1,3,3-trimethyl-, mono(methanesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 676116-95-3

CMF C26 H34 N4 S




CM 2

CRN 75-75-2


10/672949

CMF C H4 O3 S




RN 676116-98-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-8-chloro-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676117-01-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-8-chloro-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676117-02-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)




RN 676117-05-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4,4,8-trimethyl- (9CI) (CA INDEX NAME)




RN 676117-06-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-8-ethyl-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676117-09-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]propyl]-8-ethyl-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676117-10-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 676117-12-7 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 676117-14-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3-ethyl-4-methyl- (9CI) (CA INDEX NAME)




RN 676117-15-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-propyl- (9CI) (CA INDEX NAME)




RN 676117-16-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 676117-17-2 CAPLUS

CN 6(5H)-Phenanthridinone, 2-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)




RN 676117-18-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676117-19-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 676117-20-7 CAPLUS

CN 1H,5H-Benzo[ij]quinolizin-5-one, 9-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-2,3,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 676117-23-0 CAPLUS


CN 1H,5H-Benzo[ij]quinolizin-5-one, 9-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-2,3,6,7-tetrahydro-7,7-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 676117-27-4 CAPLUS


CN 4H-Pyrrolo[3,2,1-ij]quinolin-4-one, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,5,6-tetrahydro-6,6-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 676117-98-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(5-fluoro-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676117-99-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676118-01-7 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(5-chloro-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676118-02-8 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(5-methoxy-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676118-03-9 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(7-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676118-05-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676118-06-2 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(5-fluoro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676118-09-5 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)






RN 676118-10-8 CAPLUS

CN Furo[3,4-c]quinolin-4(1H)-one, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,5-dihydro-6-methyl- (9CI) (CA INDEX NAME)




RN 676118-15-3 CAPLUS

CN Furo[3,4-c]quinolin-4(1H)-one, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,5-dihydro- (9CI) (CA INDEX NAME)




RN 676118-17-5 CAPLUS

CN Furo[3,4-c]quinolin-4(1H)-one, 8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,5-dihydro- (9CI) (CA INDEX NAME)




RN 676118-19-7 CAPLUS

CN Furo[3,4-c]quinolin-4(1H)-one, 8-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,5-dihydro- (9CI) (CA INDEX NAME)




RN 676118-23-3 CAPLUS

CN 4H-Pyrrolo[3,4-c]quinolin-4-one, 8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-1,2,3,5-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 676118-27-7 CAPLUS

CN 4H-Pyrrolo[3,4-c]quinolin-4-one, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,5-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 676118-28-8 CAPLUS

CN 4H-Cyclopenta[c]quinolin-4-one, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-5-ethyl-1,2,3,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 676118-29-9 CAPLUS

CN 4H-Cyclopenta[c]quinolin-4-one, 8-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,5-tetrahydro-5-methyl- (9CI) (CA INDEX NAME)




RN 676118-31-3 CAPLUS

CN 4H-Cyclopenta[c]quinolin-4-one, 8-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propoxy]-1,2,3,5-tetrahydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676118-30-2


CMF C26 H28 N4 O2 S



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 676118-34-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,4,4-trimethyl- (9CI) (CA INDEX NAME)



RN 676118-35-7 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,3,3,4,4-pentamethyl- (9CI) (CA INDEX NAME)




IT **134017-21-3**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-3,4-dihydro-1H-quinolin-2-one **134017-22-4**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-3,4-dihydro-1H-quinolin-2-one **134017-24-6**, 6-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-3,4-dihydro-1H-quinolin-2-one

RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)

(prepn. of piperazines for treating of central nervous system disorders, in particular schizophrenia)


RN 134017-21-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 134017-22-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl- (9CI) (CA INDEX NAME)



RN 134017-24-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)






RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1991:492295 CAPLUS  
DN 115:92295  
TI Preparation of heteroarylpiperazines as antipsychotic agents  
IN Howard, Harry R.  
PA Pfizer Inc., USA  
SO Eur. Pat. Appl., 20 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 409435	A1	19910123	EP 1990-307166	19900629
	EP 409435	B1	19941026		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 9100863	A1	19910124	WO 1989-US2954	19890707
	W: FI, HU, NO, RO, SU, US				
	ES 2062374	T3	19941216	ES 1990-307166	19900629
	JP 03044388	A2	19910226	JP 1990-176120	19900703
	JP 07017633	B4	19950301		
	CA 2020611	AA	19910108	CA 1990-2020611	19900706
	US 5350747	A	19940927	US 1992-836019	19920220
PRAI	WO 1989-US2954	A	19890707		
OS	MARPAT 115:92295				
GI					






AB The title compds. [I; W1 = CR2R3; W2 = CR4R5; W3 = CR6R7; 1 of W1-W3 may be absent; R1 = (substituted) benzisoxazolyl, benzisothiazolyl, benzopyrazolyl; R2-R7 = H, alkyl, 2 of them may form alkylene, alkenylene; X1 = H, halo, C1-4 alkyl, alkoxy, NO2, cyano, etc.; Y1 = H, C1-4 alkyl, (substituted) Ph, etc.; X1Y1 = heterocyclyl; Z = C1-6 alkylene], useful as antipsychotic agents (no data), were prepd. A mixt. of piperazine deriv. II, quinolinone III (prepn. given), Na2CO3, and KI in MIBK was heated at 90.degree. under N to give 13% title compd. IV, sepd. as HCl.1/2 H2O. Also prepd. were 17 addnl. I and numerous intermediates.

IT 133999-10-7P 134017-19-9P 134017-20-2P  
 134017-21-3P 134017-22-4P 134017-23-5P  
 134017-24-6P 134017-25-7P 134017-26-8P  
 134017-27-9P 134017-28-0P 134017-29-1P  
 134017-30-4P 134017-31-5P 134017-32-6P  
 135357-15-2P 135357-16-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as antipsychotic agent)

RN 133999-10-7 CAPLUS


CN 2(1H)-Quinolinone, 7-chloro-3,4-dihydro-6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-4,4-dimethyl- (9CI) (CA INDEX NAME)



10/672949

RN 134017-19-9 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 134017-20-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 134017-21-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 134017-22-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3-methyl- (9CI) (CA INDEX NAME)




RN 134017-23-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-7-methyl- (9CI) (CA INDEX NAME)




RN 134017-24-6 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)




RN 134017-25-7 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 134017-26-8 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,7-dimethyl- (9CI) (CA INDEX NAME)



RN 134017-27-9 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-

3,4-dihydro-1,4-dimethyl- (9CI) (CA INDEX NAME)




RN 134017-28-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-1,3,3-trimethyl- (9CI) (CA INDEX NAME)




RN 134017-29-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4,4,7-trimethyl- (9CI) (CA INDEX NAME)




RN 134017-30-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-chloro-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 134017-31-5 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-7-chloro-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 134017-32-6 CAPLUS


CN 2(1H)-Quinolinone, 6-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 135357-15-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 135357-16-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=&gt; file caold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

84.00

426.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-10.95

-12.41

FILE 'CAOLD' ENTERED AT 18:59:32 ON 30 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=&gt; d his

(FILE 'HOME' ENTERED AT 18:36:02 ON 30 SEP 2005)

FILE 'REGISTRY' ENTERED AT 18:36:18 ON 30 SEP 2005

L1 STRUCTURE UPLOADED

L2 1 S L1

L3 1 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 18:39:13 ON 30 SEP 2005

L4 2 S L3

10/672949

FILE 'REGISTRY' ENTERED AT 18:44:50 ON 30 SEP 2005  
L5 STRUCTURE UPLOADED  
L6 12 S L5  
L7 315 S L5 SSS FULL  
SAVE L7 TEN672949/A

FILE 'CAPLUS' ENTERED AT 18:46:21 ON 30 SEP 2005  
L8 12 S L7

FILE 'CAOLD' ENTERED AT 18:59:32 ON 30 SEP 2005

=> s 17

L9 0 L7

=> log h

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.43	426.59

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-12.41

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 18:59:56 ON 30 SEP 2005